Video Content

15th May 19

Pharmaxis has welcomed a positive decision by an FDA Advisory Committee on Bronchitol for adult CF patients in the USA.

In this video interview CEO Gary Phillips explains the US is the last major territory where Bronchitol has not yet been approved:

Watch interview

23rd Nov 18

Proactive Investors Interview with Gary Phillips

Proactive Investors Interview with Pharmaxis Ltd CEO Gary Phillips on 23 November 2018.

Watch interview

20th Nov 18

Pharmaxis Investor Research Briefing - 20 November 2018

Pharmaxis hosted an investor research briefing on 20th November 2018 featuring presentations by a Boehringer Ingelheim global project manager and a research leader from the Garvan Institute of Medical Research. The event provided an overview of the Pharmaxis drug discovery pipeline including the anti-inflammatory drug currently being developed by Boehringer Ingelheim, work in collaboration with the Garvan Institute of Medical Research on an anti-fibrotic LOX inhibitor targeting pancreatic cancer and the anti-fibrotic LOXL2 inhibitor program.

Pharmaxis CEO Gary Phillips, Board member Dr Kathleen Metters and Head of Drug Discovery Wolfgang Jarolimek provided commercial and scientific perspectives.

Watch:

 Recordings will be available until November 2019.